Results 211 to 220 of about 1,252,486 (261)

Establishment and validation of a nomogram for predicting severe fever with thrombocytopenia syndrome complicated by invasive pulmonary aspergillosis. [PDF]

BMC Infect Dis
Yan R, Cao K, Li T, Qi H, Liu Y, Qian Y, Hao Y, Dong D, Xu Y, Gu Q.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Invasive pulmonary aspergillosis real-world outcomes: Clinical features and risk factors associated with increased mortality.

Medical Mycology, 2023
Invasive pulmonary aspergillosis is a severe fungal infection that primarily affects immunocompromised patients and is associated with high mortality. Contemporary clinical characteristics of invasive pulmonary aspergillosis and "real world" estimates ...
A. Henao-Martínez, M. Corbisiero, Ixchel T Salter, D. Chastain, G. Thompson   +4 more
semanticscholar   +1 more source

Invasive pulmonary aspergillosis

Revista Clínica Española (English Edition), 2020
AbstractInvasive pulmonary aspergillosis (IPA) remains difficult to diagnose and to treat. Most common risk factors are prolonged neutropenia, hematopoietic stem cell or solid organ transplantation, inherited or acquired immunodeficiency, administration of steroids or other immunosuppressive agents including monoclonal antibodies and new small ...
L A, Fernández-Bermejo, G, Ramírez-Olivencia   +1 more
openaire   +4 more sources

CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models

Science Translational Medicine, 2022
Aspergillus fumigatus is a ubiquitous mold that can cause severe infections in immunocompromised patients, typically manifesting as invasive pulmonary aspergillosis (IPA). Adaptive and innate immune cells that respond to A.
M. Seif, T. K. Kakoschke, F. Ebel, M. Bellet, Nora Trinks, G. Renga, M. Pariano, L. Romani, Beeke Tappe, D. Espie, E. Donnadieu, Kerstin Hünniger, A. Häder, Markus Sauer, D. Damotte, M. Alifano, P. L. White, M. Backx, T. Nerreter, M. Machwirth, O. Kurzai, Sabrina Prommersberger, H. Einsele, M. Hudecek, J. Löffler   +24 more
semanticscholar   +1 more source

Pulmonary aspergillosis

The Netherlands Journal of Medicine, 2001
Aspergillus species are ubiquitous in the environment and are inevitably inhaled into the airways. Inhalation of Aspergillus conidia or mycelium fragments may result in colonisation of the airways. In susceptible hosts colonisation may subsequently cause disease.
J F, Tomee, T S, van der Werf
openaire   +4 more sources

Invasive Pulmonary Aspergillosis

Respiration, 2002
<i>Background:</i> Invasive pulmonary aspergillosis usually occurs in immunocompromised patients. Mild abnormality of host defence is usually present in the chronic necrotising form of the disease. Acute aspergillus pneumonia usually affects patients who are seriously immunocompromised.
Sabina Skrgat, Kristan, Izidor, Kern, Ema, Music   +2 more
openaire   +4 more sources

Invasive pulmonary aspergillosis

Expert Review of Anti-infective Therapy, 2005
In susceptible patients, invasive aspergillosis has a high incidence and a mortality of up to 80%. The diagnosis of this condition is difficult, especially in the early stages of the disease and, as a consequence, antifungal therapy, despite its expense and toxicity, is often initiated empirically.
S R, Doffman, S G, Agrawal, Jeremy S, Brown   +2 more
openaire   +4 more sources

Efficacy of 12-months oral itraconazole versus 6-months oral itraconazole to prevent relapses of chronic pulmonary aspergillosis: an open-label, randomised controlled trial in India.

Lancet. Infectious Diseases (Print), 2022
BACKGROUND Chronic pulmonary aspergillosis has a 5-year mortality of 50-80% globally, and the optimal duration of treatment for chronic pulmonary aspergillosis remains unclear.
I. Sehgal, S. Dhooria, V. Muthu, K. Prasad, A. Aggarwal, A. Chakrabarti, Hansraj Choudhary, M. Garg, R. Agarwal   +8 more
semanticscholar   +1 more source

Identification of distinct immunophenotypes in chronic pulmonary aspergillosis using cluster analysis

Mycoses (Berlin), 2022
Whether chronic pulmonary aspergillosis (CPA) has different immunophenotypes remains unknown.
I. Sehgal, S. Dhooria, V. Muthu, S. Rudramurthy, K. Prasad, A. Chakrabarti, A. Aggarwal, R. Agarwal   +7 more
semanticscholar   +1 more source

Influenza-associated and COVID-19-associated pulmonary aspergillosis in critically ill patients.

The Lancet Respiratory Medicine
Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) are increasingly recognised as important complications in patients requiring intensive care for severe viral pneumonia. The diagnosis can typically
S. Feys, A. Carvalho, C. Clancy, J. Gangneux, M. Hoenigl, K. Lagrou, Bart J. A. Rijnders, L. Seldeslachts, L. Vanderbeke, F. L. van de Veerdonk, Paul E Verweij, J. Wauters   +11 more
semanticscholar   +1 more source